Literature DB >> 2474859

Malignant pleural effusions: pleurodesis using a small-bore percutaneous catheter.

F W Walsh1, W M Alberts, D A Solomon, A L Goldman.   

Abstract

This study describes our experience using a percutaneously placed small-bore catheter for drainage of malignant pleural effusions and subsequent instillation of a sclerosing agent to obliterate the pleural space. We treated 15 consecutive patients with known metastatic cancer and a symptomatic pleural effusion. Twelve patients survived for more than four weeks after the procedure; 11 of these 12 patients had a successful objective clinical response. The procedure was well tolerated, with little or no discomfort during catheter placement and the maintenance period. No serious complications were encountered. We conclude that the use of a small-bore percutaneously placed "pneumothorax" catheter in the management of malignant pleural effusions is an effective and more comfortable alternative to large-bore closed-tube thoracostomy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2474859

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

Review 1.  Management of malignant pleural effusions.

Authors:  F Grossi; M C Pennucci; L Tixi; M A Cafferata; A Ardizzoni
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

2.  Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions.

Authors:  A G Villanueva; A W Gray; D M Shahian; W A Williamson; J F Beamis
Journal:  Thorax       Date:  1994-01       Impact factor: 9.139

3.  Pigtail Catheter: A Less Invasive Option for Pleural Drainage in Egyptian Patients with Recurrent Hepatic Hydrothorax.

Authors:  Mohamed Sharaf-Eldin; Adel Salah Bediwy; Abdelrahman Kobtan; Sherief Abd-Elsalam; Ferial El-Kalla; Loai Mansour; Walaa Elkhalawany; Mohamed Elhendawy; Samah Soliman
Journal:  Gastroenterol Res Pract       Date:  2016-06-02       Impact factor: 2.260

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.